Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HIP1601 vs HGP1705 in Erosive Gastroesophageal Reflux Disease
NCT04080726Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of esomeprazole in erosive gastroesophageal reflux disease, sponsored by Hanmi Pharmaceutical. Started Oct 2018; status: completed.
02
Drugs
esomeprazole
03
Conditions
erosive gastroesophageal reflux disease
Beyond the preview
Go deeper on NCT04080726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04080726.